Aprea logo 445pt.png
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
May 16, 2022 09:21 ET | Aprea Therapeutics
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage...
POINT-Logo-Colour (1).png
POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program
May 16, 2022 08:30 ET | POINT Biopharma
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy INDIANAPOLIS,...
Affimed Logo.jpg
Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity
May 16, 2022 08:00 ET | Affimed N.V.
Correlative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapiesFirst preclinical data set on the combination of AFM28 with...
Cancer Support Community Announces Founders Award for Innovation Honoree
May 13, 2022 12:00 ET | Cancer Support Community
WASHINGTON, D.C., May 13, 2022 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC) has announced that the Janssen Pharmaceutical Companies of Johnson & Johnson will be the recipient of the...
Press release Biocartis Group NV: Results of the Annual Shareholders’ Meeting held on 13 May 2022
May 13, 2022 11:40 ET | Biocartis NV
PRESS RELEASE: 13 May 2022, 17:40 CEST Results of the Annual Shareholders’ Meeting held on 13 May 2022 Mechelen, Belgium, 13 May 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an...
Persbericht Biocartis Group NV: Resultaten van de gewone algemene aandeelhoudersvergadering gehouden op 13 mei 2022
May 13, 2022 11:40 ET | Biocartis NV
PERSBERICHT: 13 mei 2022, 17:40 CEST Resultaten van de gewone algemene aandeelhoudersvergadering gehouden op 13 mei 2022 Mechelen, België, 13 mei 2022 – Biocartis Group NV (de ‘Vennootschap’ of...
POINT-Logo-Colour (1).png
POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update
May 13, 2022 08:30 ET | POINT Biopharma
POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada...
Michael Diaz, MD Recognized by Florida Society of Clinical Oncology For Advocacy Achievements & Leadership
May 12, 2022 12:00 ET | Florida Cancer Specialists & Research Institute
Fort Myers, Florida, May 12, 2022 (GLOBE NEWSWIRE) -- Medical oncologist Michael Diaz, MD, President & Managing Physician of Florida Cancer Specialists & Research Institute, LLC (FCS), is...
Affimed Logo.jpg
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
May 12, 2022 10:31 ET | Affimed N.V.
The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells via antibody-dependent cellular cytotoxicity.AFM28 induces effective lysis of hematological...
NOVARTIS logo.jpg
Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer
May 12, 2022 10:28 ET | Novartis Pharma AG
Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new...